The present disclosure relates generally to the field of pharmaceuticals. Specifically, thepresent disclosure is directed to a compound ML-141 for the treatment, amelioration orprevention of mecamylamine-induced precipitation of nicotine dependence withdrawalsyndrome.
Inventors
Gurjeet Thakur, Imraan Rather, Sonia Dhiman
